Clinical trials
Advanced Esophageal Carcinoma clinical trials
Below are recruiting advanced esophageal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06912074RecruitingPhase 2
Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Guangzhou, GuangdongAges 18–80 - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT06354218RecruitingPhase 2
Serplulimab plus chemoradiation for older adults with esophageal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy and radiation for older adults with locally advanced esophageal cancer. It aims to see if this combination can help shrink tumors and improve outcomes without prior cancer treatment.
Nanjing, JiangsuAges 75 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07016724RecruitingPhase 2
Study of radiation and chemo with cadonilizumab for esophageal cancer
This trial tests combining radiation, chemotherapy, and the drug cadonilizumab before surgery for locally advanced esophageal squamous cell cancer. It aims to shrink the tumor and improve treatment outcomes.
Zhengzhou, HenanAges 18–75 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT06676449RecruitingPhase 3
A study on radiation-sparing treatment for advanced esophageal cancer
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06964568RecruitingPhase 3
Chemoradiation followed by immunotherapy for esophageal cancer
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
ShanghaiAges 18 years+ - NCT06474468RecruitingPhase 1/Phase 2
Study of a new drug combo for advanced esophageal cancer
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–70 - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT06773507RecruitingPhase 1
Study of BC008-1A for advanced solid tumors
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
TianjinAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT06753747RecruitingPhase 1/Phase 2
Afatinib and palbociclib for advanced esophageal cancer
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Chengdu, SichuanAges 18–75 - NCT06961526Recruiting
Preventing varices bleeding in liver cancer patients on immunotherapy
This trial tests if preventing esophageal varices (swollen veins in the food pipe) can reduce bleeding risk in people with advanced liver cancer who are receiving a combination of two drugs (atezolizumab and bevacizumab). It may help those with good liver function and no high-risk varices at the start.
Tanta, GharbyeaAges 18 years+ - NCT06374485RecruitingPhase 1
AU409 capsule for advanced liver cancer after other treatments fail
This trial tests a new capsule called AU409 for people with advanced liver cancer (HCC) who have already tried standard treatments and they no longer work. The goal is to see if AU409 can help control the cancer.
Hong KongAges 18–75 - NCT05624099RecruitingPhase 2
Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
FuzhouAges 18–75 - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06908382RecruitingPhase 2
Neoadjuvant QL1706 therapy for esophageal cancer before surgery
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Jinan, ShandongAges 18–75 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70
Hear when a new Advanced Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced esophageal carcinoma?
- Yes. Clin2 currently lists 196 recruiting advanced esophageal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced esophageal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced esophageal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.